Introduction The colon cancer pipeline has grown as pharmaceutical companies are attracted by the high incidence and success of other developers. Cytotoxics will remain an integral part of treatment, but with key brands expected to come off patent over the forecast period and the approval of new therapies, competition between targeted therapies in this lucrative indication is set to intensify. Features and benefits Quantify the performance of each of colon cancer drug in the seven major markets by brand, molecule, and regimen by sales and patient numbers. Gain insight into the key trends in individual colon cancer markets across the seven major markets. The report is accompanied by a PowerPoint presentation and Excel deliverable showing full colon cancer forecasts for the US, Japan and 5EU.
Highlights The colon cancer market will experience a modest increase from $5.7bn to just over $6bn in the seven major markets over the forecast period of 2011–20 demonstrating a compound annual growth rate of 0.59%. This relatively slow growth is a consequence of market saturation and patent expiries of key brands. The US market will remain the most lucrative market over the forecast period despite a decrease in value to $1.9bn due to patent expires of key drugs. The Japanese and five major EU markets will experience a greater growth in value as new approvals add value to relatively stable genericized cytotoxic markets. Bevacizumab will become the highest earning molecule in colon cancer by 2020 with sales of $1.4bn, but oxaliplatin will continue to be one of the most widely used therapies in the indication. Approval of new therapies will generate $1.6bn by 2020, but no single drug will recreate Avastin’s success. Your key questions answered Analysis of colon cancer drugs in the seven major markets Patient based sales forecast for drugs in the colon cancer market from 2011 to 2020 In depth analysis of the factors influencing the colon cancer market in individual countries of the seven major markets Molecule dynamics and assessment of the key colon cancer drugs in the seven major markets
Contains 53 pages and 46 tables/figures.
|